

Special Issue on
**Pushing the Boundaries in HCC Treatment: Resection,
Liver Transplantation, Targeted Therapies, and
Immunotherapy**

CALL FOR PAPERS

Hepatocellular carcinoma is the sixth most common cancer worldwide. The lack of effective systemic treatments, especially for patients with advanced disease, is one of the primary reasons for the poor prognosis of patients with HCC. The treatment of HCC must take into consideration the severity of CLD, the stage of HCC, and the clinical condition of the patient.

Liver resection (LR) is one of the most efficient treatments for patients with HCC, with the procedure being applicable to <30% of all HCC patients and 80% of the patients after LR recurrence within 5 years. On the other hand, liver transplantation for hepatocellular carcinoma (HCC) is the best treatment option for patients with early-stage tumors. The Milan criteria are the most common criteria for patient selection with HCC for transplantation, regarded as too restrictive at times though. Proposals for criteria are a debatable issue and novel surgical techniques have been developed with the aim of increasing the available pool of organs for liver transplantation, including living donor liver transplantation, donation after circulatory death, and split livers. A very promising field for development in the treatment of HCC is targeted therapies, and this requires a comprehensive understanding of the molecular signaling of HCC and identification of signaling pathways used by tumor cells to proliferate, invade, or metastasize during the progress of tumor growth. Last but not least, immunotherapy is a continuously growing field in the fight against HCC receiving major interest globally.

The aim and scope of this special issue is to focus on new cutting-edge information and research on these four different aspects of HCC treatment, the latest developments in HCC therapies that go that extra mile. We welcome submissions of research projects dealing with the targeted therapies and immunotherapies and also departments' experience and reports on improvements in patient selection and updated transplantation techniques and advances in surgical hepatic resections for better results with lower recurrence rates. Review articles on each of these four subfields of HCC treatment are also encouraged to be submitted.

Potential topics include but are not limited to the following:

- ▶ Results and reports on targeted therapies and HCC
- ▶ Breaking down of the molecular signaling in HCC
- ▶ Results and reports on immunotherapy and HCC
- ▶ Patient selection with HCC for hepatic resection and advances in the surgical approach
- ▶ Expansion of criteria for liver transplantation
- ▶ Novel surgical techniques in liver transplantation

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/cjgh/hepatology/hcct/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Alexandros Giakoustidis, Royal Free Hospital, London, UK
alexgiakoustidis@gmail.com

Guest Editors

Daniel Azoulay, Hôpital Henri Mondor, Université Paris-Est, Paris, France
daniel.azoulay@aphp.fr

Satvinder S. Mudan, Imperial College London, London, UK
mudans@aol.com

Dimitrios Giakoustidis, Aristotle University of Thessaloniki, Thessaloniki, Greece
dgiakoustidis@gmail.com

Evangelos Cholongitas, Medical School of National and Kapodistrian University of Athens, Athens, Greece
cholongitas@yahoo.gr

Submission Deadline

Friday, 3 August 2018

Publication Date

December 2018